Posts

Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger | ADVC001 lead-212 PSMA-targeted therapy and manufacturing expansion

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

cAMPfield Raises $180M to Bring PDE4 Inhibition to IBD

on

Portal Biotechnologies raises $9M for cell engineering tech that’s attracted Merck & Co., AbbVie

on

Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

on

Odyssey Therapeutics Secures $279M IPO Amid Biotech Funding Challenges

on

No Recent News Found on Samsung Biologics' $102M Strike Impact

on

Hemab and Seaport Post Gains on NASDAQ After Raising $550M Across Their Debuts

on

Avalyn Pharma Aims for $182M IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs

on

Sage Alumni Launch Tortugas with $106M to Advance CNS Pipeline

on

Kailera CEO Confident Before Record-Breaking $625M Obesity Biotech IPO

on

Trevi Therapeutics Raises $150M in Public Offering to Fund Haduvio Development

on

Recent Biotech News: MeiraGTx Reacquires Gene Therapy from J&J

on

Biogen's $5.6B Apellis Acquisition: Key Biotech Deals Including Telix's $600M Raise and Obsidian's IPO Plans

on

Kailera Outlines Plans for $528.5M IPO to Support Four Chinese Obesity Assets

on

Novartis-Backed Sidewinder Therapeutics Raises $137M Series B for Bispecific ADCs Targeting Hard-to-Treat Tumors

on